Visit https://www.peervoice.com/TWQ860 to view the entire programme with slides. After completing “Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data”, participants will be able to: Explain the rationale for targeted therapy in early-stage EGFR-mutant NSCLC; Assess recent clinical data for EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy for patients with early-stage EGFR-mutant NSCLC; and Describe how EGFR TKIs may impact the treatment paradigm for early-stage EGFR-mutant NSCLC.